Accelerate Diagnostics, Inc. (AXDXQ)
OTCMKTS · Delayed Price · Currency is USD
0.000001
0.00 (0.00%)
Inactive · Last trade price on Aug 20, 2025
Accelerate Diagnostics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 11.7 | 12.06 | 12.75 | 11.78 | 11.17 | |
Revenue Growth | -2.99% | -5.43% | 8.23% | 5.53% | 20.09% |
Cost of Revenue | 8.99 | 9.51 | 9.45 | 12.16 | 6.71 |
Gross Profit | 2.7 | 2.55 | 3.3 | -0.38 | 4.46 |
Selling, General & Admin | 21.33 | 31.23 | 39.19 | 49.24 | 46.5 |
Research & Development | 16.69 | 25.35 | 26.92 | 21.94 | 21.26 |
Operating Expenses | 38.01 | 56.58 | 66.11 | 71.18 | 67.76 |
Operating Income | -35.31 | -54.03 | -62.81 | -71.56 | -63.3 |
Interest Expense | -13.12 | -7.74 | -3.77 | -15.55 | -15.55 |
Interest & Investment Income | 0.7 | 1.12 | 0.55 | 0.09 | 0.86 |
Currency Exchange Gain (Loss) | -0.56 | 0.07 | 0.12 | -0.41 | 0.25 |
Other Non Operating Income (Expenses) | -2.63 | 12.95 | -0.23 | -0.02 | -0.06 |
EBT Excluding Unusual Items | -50.92 | -47.63 | -66.14 | -87.45 | -77.8 |
Merger & Restructuring Charges | - | - | - | - | -0.4 |
Gain (Loss) on Sale of Investments | 0.07 | 0.11 | - | - | - |
Other Unusual Items | 0.74 | -13.25 | 3.57 | 9.79 | - |
Pretax Income | -50.11 | -60.77 | -62.57 | -77.66 | -78.2 |
Income Tax Expense | -0.07 | 0.85 | -0.08 | 0.05 | 0.01 |
Net Income | -50.05 | -61.62 | -62.49 | -77.7 | -78.21 |
Net Income to Common | -50.05 | -61.62 | -62.49 | -77.7 | -78.21 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 23 | 12 | 8 | 6 | 6 |
Shares Outstanding (Diluted) | 23 | 12 | 8 | 6 | 6 |
Shares Change | 86.76% | 51.86% | 33.10% | 10.21% | 2.76% |
EPS (Basic) | -2.15 | -4.94 | -7.61 | -12.59 | -13.96 |
EPS (Diluted) | -2.15 | -4.94 | -7.61 | -12.59 | -14.00 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | -24.7 | -41.23 | -49.28 | -47.93 | -51.76 |
Free Cash Flow Per Share | -1.06 | -3.31 | -6.00 | -7.76 | -9.24 |
Gross Margin | 23.11% | 21.15% | 25.90% | -3.23% | 39.94% |
Operating Margin | -301.85% | -448.03% | -492.51% | -607.37% | -566.95% |
Profit Margin | -427.81% | -510.97% | -490.06% | -659.50% | -700.47% |
Free Cash Flow Margin | -211.17% | -341.91% | -386.47% | -406.77% | -463.56% |
EBITDA | -31.89 | -50.77 | -59.81 | -69.04 | -60.3 |
EBITDA Margin | -272.60% | - | - | - | - |
D&A For EBITDA | 3.42 | 3.25 | 3 | 2.52 | 3 |
EBIT | -35.31 | -54.03 | -62.81 | -71.56 | -63.3 |